Pfizer’s Unusual Contribution to the Afrezza Review
This article was originally published in RPM Report
Executive Summary
FDA’s portion of the advisory committee review of MannKind’s inhaled insulin included an unusual number of separate presentations (five) – and one especially unusual review based on a slide presentation from the first inhaled insulin sponsor, Pfizer.